Condition
Refractory Langerhans Cell Histiocytosis clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Refractory Langerhans Cell Histiocytosis clinical trials that are recruiting, at sites in 3 countries (most in United States (2), Australia (1), Canada (1)). By phase: Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 3Countries
All recruiting trials (2)
-
Q702 to treat blood cancers
This Phase 1 trial will test whether the oral drug Q702 is safe, tolerable, and what dose works best for adults with certain blood cancers who have failed or are not eligible for standard treatments.
-
Tovorafenib (DAY101) for relapsed or treatment‑resistant Langerhans cell histiocytosis in children and young adults
This Phase II trial tests whether tovorafenib (DAY101) can shrink or control progressive, relapsed, or treatment‑resistant Langerhans cell histiocytosis in children and young adults.
Related topics
Quick answers
How many Refractory Langerhans Cell Histiocytosis clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (2 trials), Australia (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.